Sponsored by:

ESC Congress 2009

Barcelona, Spain; August 30 - September 2

ESC 2009
Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Wednesday September 2 2009

  • Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease: the 2 year Outcomes of the SYNTAX Trial – A. Peter Kappetein

Tuesday September 1 2009

  • Effects of Valsartan on Morbidity and Mortality in Uncontrolled Hypertensive Patients With High Risk of Cardiovascular Events (KYOTO Heart Study) – Hiroaki Matsubara

  • Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) – Arthur J. Moss

  • Effects of Rolofylline in Patients With Acute Heart Failure Syndrome and Renal Impairment (PROTECT-Study) – Marco Metra

  • A Randomized Evaluation of Irbesartan versus Placebo in Patients With Atrial Fibrillation (ACTIVE-I) – Salim Yusuf

Monday August 31 2009

  • Immediate Angioplasty versus Ischemia-Guided Management After Thrombolysis for ST-segment Elevation Myocardial Infarction in Areas With Very Long Transfers (NORDISTEMI Study) – Sigrun Halvorsen

  • Primary Angioplasty versus Fibrinolysis in the Very Elderly (TRIANA Study) – Hector Bueno

  • Routine Upfront Abciximab versus Standard Peri-procedural Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for Cardiogenic Shock (PRAGUE-7 Study) – Petr Widimsky

  • Randomized Trial of 3-Limus Agent-Eluting Stents With Biodegradable or Permanent Polymer Coating (ISAR-TEST-4 Study) – Julinda Mehilli

  • The Risk of Cardiovascular Event for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial – Michelle O'Donoghue

Sunday August 30 2009

  • Randomised Controlled Trial of Low Dose Aspirin in the Prevention of Cardiovascular Events and Death in Subjects With Asymptomatic Atherosclerosis (AAA) – Gary Fowkes

  • A Randomized Comparison of A Clopidogrel High Loading and Maintenance Dose Regimen Versus Standard Dose and High Versus Low Dose Aspirin in 25,000 Patients with Acute Coronary Syndromes (CURRENT OASIS 7) – Shamir R. Mehta

  • Comparison of Ticagrelor, the First Reversible Oral P2y12 Receptor Antagonist, With Clopidogrel in Patients With Acute Coronary Syndromes: Results of the Platelet Inhibition and Patient Outcomes (PLATO) – Lars C. Wallentin

  • A Randomized Trial of Dabigatran, a Oral Direct Thrombin Inhibitor, Compared to Warfarin in 18,113 Patients With Atrial Fibrillation at High Risk of Stroke (RE-LY) – Stuart J. Connolly

  • Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes (SEPIA-ACS1 TIMI 42) – Marc Sabatine

  • Effects of Rosuvastatin on Atrial Fibrillation Occurrence: Ancillary Results of the GISSI-HF Trial – Aldo Maggioni